Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.

@article{Lipsky2000InfliximabAM,
  title={Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.},
  author={Peter E. Lipsky and D{\'e}sir{\'e}e Mfm van der Heijde and E. William St. Clair and Daniel E. Furst and F. C. Breedveld and Joachim Robert Kalden and Josef S. Smolen and Michael H. Weisman and Paul Emery and Marc Feldmann and Gregory R. Harriman and Ravinder Nath Maini},
  journal={The New England journal of medicine},
  year={2000},
  volume={343 22},
  pages={
          1594-602
        }
}
BACKGROUND Neutralization of tumor necrosis factor a (TNF-alpha) for three to six months reduces the symptoms and signs of rheumatoid arthritis. However, the capacity of this approach to effect a more sustained benefit and its effect on joint damage are not known. METHODS We treated 428 patients who had active rheumatoid arthritis despite methotrexate therapy with placebo or infliximab, a chimeric monoclonal antibody against TNF-alpha, in intravenous doses of 3 or 10 mg per kilogram of body… 

Figures and Tables from this paper

Infliximab in the treatment of rheumatoid arthritis
  • A. Perdriger
  • Medicine, Biology
    Biologics : targets & therapy
  • 2009
TLDR
Infliximab was the first monoclonal antibody to human necrosis factor alpha (TNFα) developed for treating rheumatoid arthritis and has been shown to reduce joint inflammation and to slow radiographic progression, in both clinical and non-clinical responders.
Benefit-Risk Assessment of Infliximab in the Treatment of Rheumatoid Arthritis
TLDR
Recent reports underscore the need for caution and close surveillance with the administration of TNF inhibitors, particularly given that strategies aimed at preventing toxicity remain unproven.
Evaluation of the safety of rituximab in combination with a tumor necrosis factor inhibitor and methotrexate in patients with active rheumatoid arthritis: results from a randomized controlled trial.
TLDR
The preliminary safety profile of rituximab in combination with a TNF inhibitor and MTX was consistent with the safety profile in other RA trials without a T NF inhibitor, with no new safety signals observed.
Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial.
TLDR
For patients with active RA in its early stages, combination therapy with MTX and infliximab provides greater clinical, radiographic, and functional benefits than treatment withMTX alone.
Infliximab: a review of its use in Crohn's disease and rheumatoid arthritis.
TLDR
Current data suggest that infliximab may be cost effective, especially when long-term clinical outcomes and burden of the diseases are taken into account, and more robust, prospective pharmaco-economic studies are required to better ascertain the cost effectiveness of inflIXimab.
Anti-TNF therapy for rheumatoid arthritis and other inflammatory diseases
  • P. Taylor
  • Medicine, Biology
    Molecular biotechnology
  • 2001
TLDR
Evidence to date support the hypothesis that there are 2 particularly important mechanisms of action; deactivation of the proinflammatory cytokine cascade at the site of inflammation and diminished recruitment of inflammatory cells from blood to the rheumatoid joint.
Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study.
TLDR
Even in patients without clinical improvement, treatment with infliximab plus MTX provided significant benefit with regard to the destructive process, suggesting that in such patients these 2 measures of disease are dissociated.
Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition.
TLDR
Abatacept produced significant clinical and functional benefits in patients who had had an inadequate response to anti-TNF-alpha therapy, including a clinically meaningful improvement in physical function.
Anti-TNFalpha therapy for rheumatoid arthritis: an update.
  • P. Taylor
  • Medicine, Biology
    Internal medicine
  • 2003
TLDR
For patients with established and early RA, anti-TNF therapies set a new standard for symptom control and joint protection.
...
...

References

SHOWING 1-10 OF 40 REFERENCES
Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy.
TLDR
A single infusion of 5 to 20 mg/kg infliximab significantly decreases the signs and symptoms of RA compared to placebo in patients with active disease receiving MTX.
Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein.
TLDR
In this three-month trial TNFR:Fc was safe, well tolerated, and associated with improvement in the inflammatory symptoms of rheumatoid arthritis.
A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate.
TLDR
In patients with persistently active rheumatoid arthritis, the combination of etanercept and methotrexate was safe and well tolerated and provided significantly greater clinical benefit than metotrexate alone.
Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis.
TLDR
Multiple infusions of cA2 were effective and well tolerated, with the best results occurring at 3 and 10 mg/kg either alone or in combination with MTX in approximately 60% of patients with active RA despite therapy with low-dose MTX.
The safety and efficacy of the use of methotrexate in long-term therapy for rheumatoid arthritis.
TLDR
Toxicity was noted at some time in 26 of 29 patients (90%), but reactions universally became mild and tolerable after adjustment of the dosage, and there was a significant reduction in mean prednisone dosage.
Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group.
TLDR
Clinical responses following administration of leflunomide, a new therapeutic agent for the treatment of RA, were statistically superior to those with placebo and equivalent to Those with methotrexate treatment.
Efficacy of low-dose methotrexate in rheumatoid arthritis.
TLDR
It is concluded that this trial provides evidence of the short-term efficacy of methotrexate in rheumatoid arthritis, but the mechanism of action is unknown and longer trials will be required to determine the ultimate safety and effectiveness of this drug.
Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis.
TLDR
In vivo administration of anti-TNF-alpha Ab results in the rapid down-regulation of a spectrum of cytokines, cytokine inhibitors, and acute-phase proteins, consistent with the concept of a cytokine-dependent cytokine cascade.
...
...